MediciNova, Inc.
MediciNova develops small molecule therapeutics for serious diseases with unmet medical needs. Its focusing on MN-166 for neurological disorders like MS, ALS, and substance dependence, as well as other conditions. The company also has MN-221 for asthma exacerbations, MN-001 for fibrotic diseases, and MN-029 for solid tumor cancers.
Overview
Strengths
- Price to book ratio (1.30) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (3.17) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 18.9 |
| EV/EBITDA | 11.7 |
| Price/Free Cash Flow' | 16.4 |
| ROIC | 24.0% |
| Net Debt/EBITDA | 0.9 |